By Nader's own words the cost is around $50M.
The
By Nader's own words the cost is around $50M.
The licensing deal is critical for many reasons:
1) We don't have the money to launch Leronlimab
2) We don't have in-house commercialization expertise
3) We don't have sales force (commercialization infrastructure)
4) Other companies are working on their own drugs, need to reach market before them and "impose" our drug.
BTW, you know for a fact that Syneos is the commercialization company (the one we are working-out the the deal with ?). It would make sense if this is the case.
1
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Citron Research Takes on Jim Cramer Renowned short-seller Andrew Left, representing Citron Research, has publicly critiqued Jim Cramer, a prominent figure on CNBC, regarding his optimistic view on Palantir Technologies Inc. Background of the Disagreement The clash became evident when Cramer enthusiastically tweeted about Palantir's prospects, mentioning a bold $200 price...
Continue Reading
Empowering Financial Futures: A Major Investment in Education Synchrony, a leader in consumer financing, recently made an impactful announcement regarding its endeavor to enhance financial education across the nation. The company has pledged $1 million over two years to nonprofit organizations dedicated to helping K-12 public educators effectively teach personal finance....
Continue Reading
ModelOp Summit Set to Explore AI Governance Innovations ModelOp is gearing up for its third annual virtual AI Governance Leadership Summit, where it will feature insightful discussions led by industry experts. A highlight of this year’s event is the keynote address by Sangame Krishnamani, a respected Director of Software Engineering at Capital One. The summit will take...
Continue Reading
Paratus and Low Carbon's Strategic Alliance In an exciting development for the renewable energy sector, Paratus Holdings Limited, a pioneering (re)insurance firm focused on energy price risk, has entered into a strategic collaboration with Low Carbon, an esteemed independent power producer (IPP). This partnership aims to safeguard the revenue streams of Low Carbon's...
Continue Reading
SamSan SLC Unveils OXCUS Series of PFAS-Free Lubricants SamSan SLC, a prominent solid lubricant coating manufacturer, has made an exciting announcement regarding its new product line—the OXCUS Series. This innovative product line features a unique, PFAS-free dry film lubricant, marking a significant advancement in eco-friendly material science. The Need for Sustainable...
Continue Reading